Recent Articles from this contributor
An Investor’s Guide to GLP-1 Drugs: Beyond Biopharma Stocks
In part one of a series, analyst Ling Han discusses the potential impact of GLP-1 drugs to healthcare stocks not directly involved in the development and manufacture of the medical world’s latest pharmaceutical phenomenon
GLP-1: Healthcare’s Latest Investment Mega Theme
AGF analyst Ling Han discusses the pharmaceutical drug front and center with healthcare investors.